Connect your AI

Alto Neuroscience ANRO Convertible Debt

Other financials

Income statement

Operating income-$27.1M-73.1%

Net income-$26.2M-73.0%

EPS (diluted)-$0.80-42.9%

Balance sheet

Cash & equivalents$264.3M+63.9%

Total debt$20.9M-17.2%

Total equity$243.4M+75.0%

Total assets$276.3M+60.7%

Cash flow

Operating cash flow-$27.1M-63.6%

CapEx$556.0K+2,217%

Free cash flow-$27.6M-66.7%

Valuation

Market cap$887.88M+1,358%

Enterprise value$644.49M-958%

Returns & leverage

Return on equity-38.9%+0.9pp

Debt / equity0.1×-0.1×

Current ratio20.5×-2.0×

Where this comes from

Reported directly by Alto Neuroscience in its filing.

Tagged under the XBRL concept us-gaap:ConvertibleDebt.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's convertible debt.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Alto Neuroscience's convertible debt?: Alto Neuroscience (ANRO) reported convertible debt of $2.34M in Q1 2026.
How has Alto Neuroscience's convertible debt changed year-over-year?: Alto Neuroscience's convertible debt increased by 92.8% year-over-year, from $1.21M to $2.34M.